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Background. Cryptococcal meningitis (CM) is a leading cause of HIV-associated mortality globally. High fungal 
burden in cerebrospinal fluid (CSF) at diagnosis and poor fungal clearance during treatment are recognized 
adverse prognostic markers; however, the underlying pathogenic factors that drive these clinical manifesta-
tions are incompletely understood. We profiled a large set of clinical isolates for established cryptococcal 
virulence traits to evaluate the contribution of C. neoformans phenotypic diversity to clinical presentation and 
outcome in human cryptococcosis.
Methods. Sixty-five C. neoformans isolates from clinical trial patients with matched clinical data were assayed in 
vitro to determine murine macrophage uptake, intracellular proliferation rate (IPR), capsule induction, and 
laccase activity. Analysis of the correlation between prognostic clinical and host immune parameters and fun-
gal phenotypes was performed using Spearman’s r, while the fungal-dependent impact on long-term survival 
was determined by Cox regression analysis.
Results. High levels of fungal uptake by macrophages in vitro, but not the IPR, were associated with CSF fungal 
burden (r = 0.38, P = 0.002) and long-term patient survival (hazard ratio [HR] 2.6, 95% CI 1.2–5.5, P = 0.012). 
High-uptake strains were hypocapsular (r = –0.28, P = 0.05) and exhibited enhanced laccase activity (r = 0.36, 
P = 0.003). Fungal isolates with greater laccase activity exhibited heightened survival ex vivo in purified CSF 
(r = 0.49, P < 0.0001) and resistance to clearance following patient antifungal treatment (r = 0.39, P = 0.003).
Conclusion. These findings underscore the contribution of cryptococcal-phagocyte interactions and laccase- 
dependent melanin pathways to human clinical presentation and outcome. Furthermore, characterization 
of fungal-specific pathways that drive clinical manifestation provide potential targets for the development of 
therapeutics and the management of CM.
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Introduction
Cryptococcal meningoencephalitis (CM), caused by the fungus 
C. neoformans, is a leading cause of mortality in HIV-infected individ-
uals globally (1). Sub-Saharan Africa, with the highest HIV burden, 
is the most affected region, accounting for 80% of all CM-associated 
mortality, despite access to antiretroviral therapy (ART) (2, 3).
HIV-associated CM is characterized by a paucity of inflamma-
tion and a large fungal burden in the cerebrospinal fluid (CSF) at 
diagnosis (4, 5). In addition to high baseline fungal burden and a 
poor proinflammatory immune response, altered mental status 
and a slow rate of fungal clearance upon treatment are associated 
with acute mortality (6–8). Understanding the factors that link 
these prognostic markers with cryptococcal virulence is crucial for 
the development of effective anticryptococcal therapy.
Cryptococcal infection is acquired through inhalation of cryp-
tococcal spores or desiccated yeast cells into the lung, where the 
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fungus is either cleared or maintained in an asymptomatic latent 
state by effective host immunity (9). In immunocompromised 
hosts, however, cryptococci can disseminate from the lungs to 
other organs, in particular the central nervous system (CNS), 
where the fungus causes a usually fatal meningoencephalitis 
(10). The variation in CM severity and outcome between individ-
ual patients may be explained by underlying deficiencies in the 
host immune response (11, 12) and/or the virulence capacity of 
the infecting strain (13, 14). In addition to the ability to grow at 
physiological temperature (37°C), capsule expression, melanin 
production by laccase, and macrophage parasitism are all major 
virulence attributes that allow the pathogen to evade and over-
whelm the immune system (15).
To date, most studies providing mechanistic links between cryp-
tococcal virulence and outcome have been conducted in rodent 
models using laboratory reference strains. It remains unclear 
how these data relate to human infections. We report here for the 
first time, to our knowledge, a large-scale analysis of the relation-
ship between the cryptococcal virulence factors (growth rate at 
37°C, capsule expression, laccase activity, phagocytic uptake and 
intracellular proliferation in macrophages) and patient clinical 
parameters. We show that CNS fungal burden and consequent 
patient death are associated with high cryptococcal uptake by 
macrophages. Thus, effective phagocytosis counterintuitively pre-
disposes to poor outcome upon cryptococcal infection. Finally, we 
show that laccase activity is associated with cryptococcal survival 
in human CSF ex vivo and poor in vivo CSF fungal clearance over 
a 2-week period of antifungal treatment.
Results
High cryptococcal uptake by macrophages is associated with high patient 
CSF fungal burden. In Cryptococcus gattii infections of immunocom-
petent hosts, intracellular proliferation within phagocytes cor-
relates with virulence in a murine model of cryptococcosis (16). 
Using a large patient-matched set of clinical isolates and the estab-
lished murine macrophage–like cell line J774 (see Table 1 for a 
summary of patient baseline characteristics, isolate genotype, and 
in vitro phenotype), we tested whether a similar relationship exists 
for C. neoformans, but found no significant correlation between 
the intracellular proliferation rate (IPR) and patient fungal bur-
den upon presentation (Spearman’s rank correlation r = –0.2, 
P = 0.22). However, we found a positive correlation between fungal 
burden in the CNS and phagocytic uptake of opsonized cryptococci 
(r = 0.38, P = 0.002; Figure 1A). We divided isolates into high- and 
low-uptake groups, based on median uptake (378 cryptococci/μl 
lysate), which confirmed that fungal burden in the high-uptake 
group of isolates was significantly higher than in the low-uptake 
isolates (P < 0.001, unpaired t test; Figure 1B).
Macrophage uptake, not intracellular proliferation, drives intracellular 
fungal load in C. neoformans. To dissect this relationship, we ana-
lyzed the relationship between uptake and intracellular prolif-
eration. This analysis showed that uptake and IPR are inversely 
correlated in this set of isolates (r = –0.37, P = 0.003), implying 
that highly phagocytosed isolates have lower intracellular prolif-
eration rates. However, high-uptake isolates had a larger quantity 
of intracellular cryptococci at 18 hours than the low-uptake coun-
terparts, exhibiting a strong positive correlation between uptake 
at 2 hours and intracellular cryptococcal load (ICL) at 18 hours 
of incubation (r = 0.90, P < 0.0001). High phagocytosis coupled 
with minimal proliferation was enough to drive intracellular fun-
gal burden in the high-uptake isolates, suggesting a high retention 
and survival of the initially phagocytosed cryptococci inside the 
macrophage. Thus, for C. neoformans, the intracellular burden of 
cryptococci within macrophages appeared to be driven primarily 
by the rate at which the pathogen was engulfed and not by subse-
quent proliferation within macrophages (Figure 2).
To test whether the uptake phenotype is host specific, we repeated 
the phagocytosis assay using a selection of high-uptake and low-
uptake isolates (5 strains from each group) and human primary 
monocyte–derived macrophages. This analysis showed a significant 
(r2 = 0.8, P < 0.001, linear regression) correlation with uptake by J774 
macrophages, suggesting that the traits mediating cryptococcal 
uptake by macrophages were conserved in these isolates and could 
be recognized by both murine and human macrophages (Figure 3).
We next tested whether the high-/low-uptake effect was opsonin 
dependent. Using the same set of 10 strains (tested in both J774 
and human primary macrophages), we examined uptake following 
Table 1
Patient baseline characteristics, isolate genotype, and phenotype
  ValueA
Patient baseline characteristics
 Age (years) 32 (19–55)
 Male (%) 28 (43%)
 CD4 count 26 (2–242)
 Altered mental status (%) 19 (29%)
CSFB
 Protein (g/l) 0.9 (0.13–5)
 Glucose (mmol/l) 2.2 (0.1–4.8)
 White cell count (cells/μl) 13 (0–1215)
 IFN-γ (log10 pg/ml) 1.7 (0–2.7)
 TNF-α (log10 pg/ml) 1.0 (–0.1–2.1)
 IL-6 (log10 pg/ml) 2.8 (–0.14–3.2)
 Opening pressure (cm H2O) 26 (5–80)
 Fungal burden (log10 CFU/ml) 5.8 (2.5–6.9)
 Rate of fungal clearance (CFU/ml CSF/day)C –0.4 (–0.9 – –0.03)
Deaths (%)
 2 weeks 10 (15%)
 10 weeks 22 (34%)
 52 weeks  32 (49%)
Pathogen genotype and in vitro phenotype
 GenotypeD (%) VNI (46%), VNII (15%),  
  VNB (11%)
 Doubling time at 37°C (hours) 4.2 (3.1–11.2)
 Laccase activity (U)E 345 (21–1,118)
 Capsule diameter (μm) 1.9 (1.2–4.2)
 Uptake (cryptococci/μl lysate at 2 hours) 378 (109–1,613)
 Intracellular proliferation rateF 2.7 (1.14–4.7)
 ICL (cryptococci/μl lysate at 18 hours) 999 (322–2,842)
 Survival in CSF (CFU/ml CSF/d)G –1.0 (–3.5–0.07)
AValues are for 65 isolates derived from 65 patients and are the median 
(range), unless otherwise stated. BCSF inflammation is represented by 
total white blood cell count and the level of proinflammatory cytokines 
IFN-γ, TNF-α, and IL-6. CRate of CSF fungal clearance (mean decrease 
in CFU/ml CSF/day). DTwo of the 65 isolates were not genotyped. ELac-
case activity was quantified spectrophotometrically by assessing pig-
mentation at 475 nm (0.001 OD475 nm = 1 U laccase) and standardized 
as the ratio to the reference strain H99. FThe IPR was determined as the 
ratio of ICL at 18 hours to the number of engulfed cryptococci (uptake) 
at 2 hours of incubation. GCryptococcal survival in CSF was measured 
as the rate of decrease in the number of viable cryptococci per day 
(CFU/ml CSF/day).
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2 hours of macrophage infection in the absence of any opsonin 
(i.e., in serum-free media without the addition of anticapsule mAb 
18B7). High-uptake strains again showed better engulfment than 
low-uptake strains (median 438 vs. 60 cryptococci/μl lysate after a 
2-hour exposure to macrophages, P = 0.02, Mann-Whitney U test), 
suggesting that this phenotype is an intrinsic feature of the patho-
gen and not a reflection of variable opsonin deposition (Figure 4).
Cryptococcal uptake by macrophages and CSF IFN-γ levels are indepen-
dently associated with fungal burden. To gain insight into other host 
factors that could influence fungal burden, we performed univari-
able analysis of patient CSF immune parameters, including total 
CSF white blood cell count and CSF cytokines and chemokines 
IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, GM-CSF, MCP1, MIP1α, 
RANTES, VEGF, IFN-γ, and TNF-α, at the time of CM diagnosis. 
CSF IFN-γ levels were significantly associated with fungal burden 
(P = 0.001, linear regression). We then used a multivariable regres-
sion model to ask whether in vivo IFN-γ and in vitro cryptococcal 
uptake were interdependent in influencing fungal burden. Both 
uptake and IFN-γ remained independently associated with CSF 
fungal burden (P = 0.003 and 0.004, respectively).
Infection with high-uptake strains increases the risk of death. Using Cox 
regression analysis, we explored the impact of the macrophage- 
cryptococcal uptake relationship on patient survival, including an 
adjustment for fungal burden. Ten weeks after diagnosis, there was a 
trend toward worse survival in the high-uptake group (hazard ratio 
[HR] 2.2, 95% CI 0.9–5.6, P = 0.095, Figure 5), which became signifi-
cant on long-term follow-up (HR 2.6, 95% CI 1.2–5.5, P = 0.012). The 
link between macrophage cryptococcal uptake and patient survival 
is likely partly mediated through fungal burden. Adjusting for CSF 
fungal burden rendered the 10-week uptake-survival association 
nonsignificant (HR 2.0, 95% CI 0.8–5.3, P = 0.14).
High CSF fungal burden is most likely a reflection of meningeal or brain 
parenchymal infection, not replication in situ. At the time of CM diag-
nosis, there is often a high organism load in the CSF, an indication 
either of cryptococcal “immigration” from other body sites, or an 
ability to proliferate within the CNS. We tested the latter possibil-
ity through ex vivo exposure of the strains to normal human CSF. 
None of the isolates grew in CSF, and in most cases, fungal burden 
dropped significantly during incubation over a 96-hour period 
(mean rate of decrease of –1.1 log10 CFU/ml per day of incubation), 
suggesting that high fungal burden in the CNS may be due to rep-
lication in the brain parenchyma rather than in the CSF, which may 
just reflect “spillover” from the brain and meninges (Figure 6A). As 
controls, isolates were grown in nutrient-rich Saboraud dextrose 
broth (SDB) nutrient–deficient PBS and in 1% saline at pH 5.6, 
7.4, 8.5, and 10. Isolates grew efficiently in SDB (mean ± SD rate 
of increase 0.47 ± 0.11 CFU/ml SBD/day) and had comparatively 
better survival in PBS (0.012 ± 0.067) and saline (–0.001 ± 0.033) 
than in CSF, indicating that cryptococcal failure to grow in CSF 
was neither nutrient nor pH dependent (Figure 6B).
High-uptake strains are hypocapsular. High-uptake and low-uptake 
strains showed similar in vitro growth rates in SDB at 37°C 
(mean ± SD doubling time of 4.1 ± 0.16 hours and 4.9 ± 0.36 
hours, respectively, P = 0.1, unpaired t test), which correlated nei-
ther with uptake nor with patient CSF fungal burden. Following 
capsule induction for all strains, the average capsule diameter was 
inversely correlated with macrophage uptake (r = –0.28, P = 0.05; 
mean ± SD diameter 1.9 ± 0.7 μm for high-uptake and 2.2 ± 0.5 
μm for low-uptake strains). Thus, as previously reported, the cap-
sule represents a major inhibitor of phagocytic uptake in both 
opsonic and nonopsonic conditions (17). We did not find any 
Figure 1
Association of cryptococcal uptake by macrophages with patient fun-
gal burden. (A) Positive correlation between cryptococcal uptake by 
J774 macrophages and patient CSF fungal burden. (B) The average 
log CSF fungal burden was significantly higher in the high-uptake than 
in the low-uptake group of isolates. Mean ± SEM, 5.856 ± 0.1457 and 
4.922 ± 0.2189, respectively, P < 0.001. n = 32 in each group of isolates.
Figure 2
Relationship between uptake, IPR (r = –0.37, P = 0.003), and ICL. 
Uptake was inversely correlated with IPR and positively correlated with 
ICL (r = 0.90, P < 0.001).
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correlation between induced capsular diameter and ex vivo quan-
tification of shed capsular material (cryptococcal antigen titer; 
n = 47, Spearman’s r –0.07, P = 0.59), nor did the cryptococcal anti-
gen titer in CSF correlate with phagocytic uptake in vitro (n = 47, 
Spearman’s r = 0.14, P = 0.27) or patients’ CSF opening pressure 
(n = 56, Spearman’s r –0.08. P = 0.56), in line with our previous 
findings in a larger cohort (18). Thus, a reduced capsular diam-
eter is likely to drive more effective uptake by host phagocytes 
without necessarily impacting the systemic immunomodulatory 
effects that result from the shedding of capsular material.
High-uptake strains showed high laccase activity, separate from an effect of 
melanin production. The cryptococcal enzyme laccase is a well-char-
acterized virulence factor, which oxidizes both iron and polyphe-
nols, producing a protective melanin cell wall coat (19), and modi-
fies prostaglandin synthesis (20). We tested laccase activity in vitro 
by quantifying the production of black melanin-like pigment upon 
exposure to L-3,4-dihydroxphenylalanine (L-DOPA) medium. 
Laccase activity was positively correlated with uptake (r = 0.36, 
P = 0.003), indicating that the more effectively phagocytosed iso-
lates had higher laccase activity. To demonstrate whether this was 
mediated through differences in melanin production, we quan-
tified cell wall melanin by generating melanin ghosts using acid 
digestion (21) for ten clinical strains with the highest (n = 5) and 
the lowest (n = 5) laccase activity. We found no significant correla-
tion between cell wall melanin levels and uptake (P = 0.1). Given 
the small sample size, this does not entirely rule out the association 
of melanization with phagocytosis. Alternatively, the association 
of laccase activity with efficient phagocytosis may be mediated by 
an additional role of the laccase enzyme (e.g., in iron scavenging 
or inflammatory regulation), separate from its effect on melanin.
Cryptococcal laccase activity is associated with ex vivo CSF survival 
and the in vivo rate of fungal clearance. Laccase activity and survival 
in human CSF showed a significant positive correlation (r = 0.49 
and P < 0.0001) (Figure 7A). Interestingly, we also observed a sig-
nificant correlation between laccase activity and the in vivo rate of 
CSF fungal clearance on amphotericin-based antifungal therapy 
over a 2-week treatment period (r = 0.39, P = 0.003) (Figure 7B). 
Thus, high laccase activity appears to enhance survival within 
human CSF, both in the presence and absence of antifungals.
Discussion
In this study of the virulence phenotype of clinical C. neoformans 
isolates, we have shown an association of two cryptococcal vir-
ulence traits, macrophage uptake and laccase activity, with fun-
gal burden and rate of clearance of infection, two in vivo adverse 
prognostic markers in CM, and mortality. Infection with cryp-
tococcal strains exhibiting high-uptake and high laccase activity 
was correlated with higher pretreatment CSF fungal burden and 
poor cryptococcal clearance from CSF on antifungal therapy, sig-
nificantly increasing the likelihood of death from CM. We have 
demonstrated, to our knowledge, the first direct link between 
these pathogen virulence factors and poor clinical outcome in 
HIV-associated CM. Importantly, by drawing on isolates from five 
clinical trials, four of which were conducted at different times and 
in different regions of South Africa and the fourth conducted in 
Thailand (4, 22–25), our analysis includes a diverse set of human 
hosts, pathogen genotypes, and commonly used antifungal treat-
ment regimens. Our findings are thus likely to reflect common vir-
ulence traits associated with clinical phenotypes in patients across 
a wide spectrum of cryptococcal disease.
The key, and perhaps surprising, observation arising from this 
study is that strains showing high engulfment by phagocytes in 
vitro were associated with higher fungal burden in patients. Inter-
estingly, this correlation does not reflect higher replication rates 
either extracellularly in nutrient-rich medium or intracellularly, 
as measured by doubling time at 37°C, or higher IPRs; nor did we 
see evidence of growth using an ex vivo CSF model. Instead, we 
Figure 3
Cryptococcal uptake by J774 macrophages correlates with uptake by 
human macrophages. High-uptake (n = 5) and low-uptake (n = 5) iso-
lates were independently exposed to murine macrophage–like cell line 
J774 and primary human macrophages for 2 hours at 37°C. The rate of 
uptake in J774 macrophages was consistent with that in human mac-
rophages (P < 0.001, linear regression).
Figure 4
Cryptococcal uptake by macrophages in the absence of either anti-
body or complement opsonization. (A) High-uptake (HU) strains were 
significantly more engulfed by macrophages in the presence of opso-
nin (anticapsule antibody 18B7) and (B) in the absence of opsonin 
compared with low-uptake (LU) strains. Solid black lines represent the 
median uptake within a group of strains for four experimental repeats.
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hypothesize that strains that are more easily phagocytosed have a 
higher chance of intracellular survival within phagocytes and thus 
of more efficient dissemination to the brain, resulting ultimately 
in a higher CNS fungal burden and poorer patient outcome. 
In this context, it is interesting to note that Rohatgi et al. very 
recently reported that a higher-affinity variant of the phagocytic 
receptor FcγRIIIA is a risk factor for HIV-associated cryptococcal 
disease (26). Thus, both host factors (26) and pathogen factors 
(this study) that enhance phagocytic uptake appear to increase the 
risk of (severe) cryptococcal disease.
Cryptococcal nonlytic escape and spread from cell to cell has 
been described in in vitro cultures of both murine and human 
macrophages (27–29) and has been recently confirmed to occur 
in vivo in a murine model of cryptococcosis (30). Moreover, cryp-
tococci-laden macrophages have been observed in the brain cap-
illaries and leptomeninges of a mouse with severe cryptococcal 
meningitis (31). The ability of monocytes to systemically dissem-
inate the fungus to the brain has further been demonstrated in a 
mouse model of cryptococcosis (32). These observations point to 
the potential of phagocytes to drive host fungal burden through 
the uptake of fungal cells, providing a niche for cryptococcal sur-
vival in the host and spreading it from the site of infection to the 
brain in a “Trojan horse” model.
The cryptococcal capsule is well described for its role in resist-
ing phagocytosis (17), and thus possession of a smaller capsule 
may partly explain why high-uptake isolates were easily engulfed 
by macrophages. In the environment, such a phenotype is likely to 
be deleterious, since fungi will be effectively engulfed and killed by 
soil amoebae and other predators. Thus, cryptococcal strains caus-
ing human CM are most likely a selected subset of a more diverse 
environmental population and happen to exhibit a combination 
of rapid engulfment but good intracellular survival.
We also observed that strains exhibiting high phagocytic uptake 
also exhibited higher laccase activity. Laccase is a critical enzyme 
for the synthesis of melanin, a pigment that is protective against 
both macrophage antimicrobial activities (such as the reactive 
oxygen burst) and amphotericin B, a drug that is the basis of the 
induction of CM therapy, including in our patients (33–35). Acid 
extraction of a small subset of these strains showed no significant 
correlation between phagocytic uptake and cell wall melanin. 
This may have been due to the small sample size (n = 10); alter-
natively, the link between laccase activity and phagocytic uptake 
in this group of isolates may reflect one of the other functions 
of this enzyme. In particular, it is tempting to speculate that the 
production of prostaglandins by cryptococci, which is a laccase- 
Figure 5
Kaplan-Meier survival curve estimates of patients infected with high-
uptake (solid line) versus low-uptake (dotted line) isolates out to 
10-week follow-up (HR 2.2, 95% CI 0.9–5.6, P = 0.095).
Figure 6
Cryptococcal survival in ex vivo human CSF. (A) Survival of 65 clini-
cal C. neoformans strains exposed to human CSF over 4 days. None 
of the strains proliferated in CSF; each black line represents the sur-
vival of one isolate over 4 days, and the gray line represents the mean 
survival for all strains. Survival slope was calculated as the mean 
rate of increase or decrease of CSF cryptococcal counts per day of 
incubation, derived by averaging the slope of the linear regression of 
log10 CFU/ml over time for each isolate. (B) Testing for whether the 
growth inhibition effect of CSF was nutrient or pH dependent. Two 
clinical strains (CCTP13 and CM50) were grown in SDB (positive 
control), nutrient-deficient PBS, and 1% saline (average per strain 
of survival at pH 5.6, 7.4, 8.5, and 10). Strains grew exponentially in 
SDB and maintained a stable population in PBS and saline but were 
gradually killed in CSF.
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dependent phenotype (20), may be driving differences in phago-
cytic efficacy. Of note, our laccase activity assay used L-DOPA as a 
medium, and in vitro melanization may be different from in vitro 
polymerization of L-DOPA. Several possible substrates exist for 
melanization by cryptococcal laccase, including the indole com-
pounds described by Kwon-Chung in 1983 (36).
Our aim was to look for pathogen virulence factors that are 
linked to patient clinical phenotype and to interrogate relation-
ships with host factors that are important for the control of infec-
tion. Patients’ CSF fungal burden and rate of clearance have been 
demonstrated to be modulated by the nature of the host phago-
cyte response and proinflammatory cytokines, in particular IFN-γ, 
both within and outside the CNS (11, 12). We observed that CSF 
fungal burden was negatively associated with CSF IFN-γ levels. 
Taken together, these associations, in the HIV-infected host, are 
indicative of a host environment with inactivated phagocytes (37) 
due to a paucity of IFN-γ, in which the easily phagocytosed cryp-
tococcal strains thrive and proliferate, resulting in a greater fungal 
burden. This is in contrast to C. gattii infection in the immunocom-
petent host, in which a strong adaptive immune response results 
in appropriate macrophage activation and in which the ability to 
rapidly replicate in macrophages is likely to be more important 
for virulence (16). In HIV-infected patients with CM, we propose 
that the ease of uptake of cryptococci by macrophages, coupled 
with the inability to orchestrate an effective IFN-γ–activated fun-
gicidal macrophage response, results in unchecked proliferation 
and survival of the fungus, with dissemination to the CNS yield-
ing high fungal burden. We also suggest that high laccase activity 
in C. neoformans increases cryptococcal intracellular (macrophage) 
and extracellular (CSF) survival and confers resistance to antifun-
gal killing. Although we did not demonstrate a clear relationship 
between laccase activity and cell wall melanin production, this 
may have been due to the limitations of the in vitro assay and the 
small sample size. Melanization has been demonstrated in crypto-
cocci in human brain tissue (38). The catecholamine substrates for 
melanization in the human brain include more than just L-DOPA, 
so it remains possible that the association between laccase activity 
and clearance of infection during amphotericin treatment is still 
mediated through an effect on in vivo melanin production. Alter-
natively, laccase, through alternative pathways, may protect Crypto-
coccus from the toxic free radicals and proinflammatory cytokines 
generated by amphotericin B (39).
In summary, our study has shown that the relationship between 
the macrophage-cryptococcal interaction and poor clinical out-
come is mediated through increased patient fungal burden. Build-
ing on a recent study linking macrophage-cryptococcal interaction 
to high mortality at 1 year of follow-up in HIV-associated CM 
(14), we have shown an association with mortality at 10 weeks in 
our cohort, a time when most mortality is attributed to CM as 
the major cause of death. Furthermore, we are the first to demon-
strate an association of laccase activity and poor CSF fungal clear-
ance during amphotericin-based treatment of human CM, which 
may either be mediated through an effect on melanization in vivo 
or through an alternative immunomodulatory effect of laccase. 
These findings underscore the importance of cryptococcal-phago-
cyte interactions and the laccase-dependent melanin pathway and 
their relevance to human clinical outcome and identify these as 
important targets for future therapeutics and management of CM.
Methods
Patients and isolates
A total of 65 cryptococcal isolates were assayed from a cohort of more 
than 300 clinically characterized HIV-associated CM patients from five 
completed clinical trials in Thailand and South Africa (4, 22–25). Partic-
ipants provided written informed consent, and all trials were approved 
by the local research ethics committees as well as the ethics committee 
of Wandsworth (London, United Kingdom). Isolates for this study were 
selected to reflect the range of clinical trials, geographic locations, and 
isolate genotypes of serotype A C. neoformans var. grubii. Genotypes were 
determined using multilocus sequence typing (MLST) according to the 
ISHAM (International Society for Human and Animal Mycology) con-
sensus typing scheme (40). All isolates included were from patients who 
were ART naive at enrollment and treated for a first episode of CM with 
amphotericin B–based therapies (sometimes in combination with fluco-
nazole, flucytosine, or adjuvant IFN-γ). Patient baseline characteristics 
including mental status, CSF white cell count, protein levels, cytokine 
levels, opening pressure, and fungal burden were determined before 
therapeutic intervention.
Cryptococcal culture
The reference serotype A C. neoformans var. grubii strain H99 (obtained from 
R.C. May’s laboratory at the University of Birmingham) was used as the 
control strain in all assays. Prior to assay, clinical isolates and H99 were 
propagated either in yeast peptone dextrose (YPD) broth (1% yeast extract, 
1% peptone, and 2% glucose; Sigma-Aldrich) or on SDA (Thermo Fisher Sci-
entific) at 30°C. Infection inocula were made from 24-hour starter cultures 
in YPD broth or SDB (Thermo Fisher Scientific) at 37°C with rotation.
Figure 7
Association of laccase activity with ex vivo cryptococcal survival in 
CSF and the in vivo rate of fungal clearance. (A) Higher survival in CSF 
by high laccase activity isolates. (B) High laccase activity isolates were 
cleared less effectively from patient CSF during antifungal treatment.
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Macrophage culture
The murine-derived J774 macrophage cell line and human monocyte–
derived macrophages were used for the study. Prior to use, 1.0 × 105 J774 
macrophages were grown in 24-well tissue culture plates (Greiner) con-
taining DMEM supplemented with 10% FBS, 1 mM L-glutamine, and 1% 
penicillin-streptomycin (Sigma-Aldrich) for 24 hours at 37°C with 5% CO2. 
The macrophage batches used were kept within the range of three passages 
to limit passage-to-passage variations.
Primary human macrophages were derived from peripheral blood 
monocytes from healthy donor buffy coats (National Blood Service, 
United Kingdom). PBMCs were isolated by Ficoll (Sigma-Aldrich) gradient 
centrifugation, and monocytes were purified from the PBMC population 
by adherence to plastic following overnight culture in tissue culture flasks 
(T75 Greiner) in RPMI 1640 medium with L-glutamine (Gibco), supple-
mented with either 10% AB male human serum (First Link) or 10% FBS 
(Sigma-Aldrich) plus 1% penicillin-streptomycin, in the presence of 1,000 
U/ml GM-CSF. Monocytes were detached and counted by hemocytometer 
to achieve a final cell density of 5 × 105 cells per well in a 24-well tissue cul-
ture plate (Corning). Cells were maintained for 7 to 14 days in RPMI 1640 
medium supplemented with 10% FBS and 1% penicillin-streptomycin for 
differentiation into macrophages. The medium was changed every 3 days.
Phagocytosis and intracellular proliferation assay
Isolates were tested for the rate at which they were phagocytosed by 
(uptake) — and proliferated inside (IPR) — macrophages. Prior to infection, 
J774 macrophages were activated with 15 μg/ml PMA for 30 to 40 minutes 
in serum-free medium (DMEM with L-glutamine and 1% penicillin-strep-
tomycin). Cryptococci were harvested from the 24-hour starter culture by 
centrifugation, washed twice in PBS, and opsonized with 1 μg/ml of the 
anticapsule mAb 18B7 (provided by Arturo Casadevall, Albert Einstein 
College of Medicine, New York, New York, USA) for 30 to 60 minutes at 
room temperature. Macrophages were then exposed to the opsonized cryp-
tococci at a 1:10 ratio and incubated for 2 hours at 37°C with 5% CO2 to 
promote phagocytosis. After 2 hours, the medium was removed, and mac-
rophages were extensively washed (4–5 times) with sterile PBS to remove 
extracellular cryptococci. Part of the culture (time point 0) was lysed with 
200 μl of sterile water for 20 minutes at 37°C to release intracellular cryp-
tococci, which were counted using a hemocytometer. The remaining cul-
ture was maintained in serum-free medium at 37°C, and cells were lysed 
and intracellular cryptococci were counted at 18, 24, and 48 hours after 
infection. The rate of phagocytosis (uptake) was determined as the number 
of cryptococci engulfed by macrophages 2 hours after infection. The IPR 
was determined as the ratio of the number of intracellular cryptococci at 
18 hours to the number of intracellular cryptococci at 2 hours. Results 
were expressed as the mean of 5 to 7 experimental repeats. Ten isolates were 
selected from the J774 macrophage uptake profile, representing the top 5 
(high-uptake) and bottom 5 (low-uptake) strains and then tested in pri-
mary human macrophages. The human monocyte–derived macrophages 
were stimulated with 1,000 U/ml human recombinant IFN-γ (Immuno-
tools) and 10 μg/ml LPS (Sigma-Aldrich) 24 hours prior to infection. The 
rate of cryptococcal uptake and the IPR were determined as described 
above with J774 macrophages. To evaluate opsonin influence on crypto-
coccal uptake, the experiment was repeated with nonopsonized crypto-
cocci, and the rate of uptake was determined after 2 hours of incubation 
at 37°C with 5% CO2.
Laccase activity
Isolates were grown for 12 hours in SDB at 37°C with shaking at 200 rpm. 
The growth medium was removed, and the yeast cells were washed twice 
in PBS, counted by hemocytometry, and adjusted to achieve an inoculum 
of 4 × 106 cells/ml. Cryptococci were then incubated in L-DOPA medium 
(0.1% glucose anhydrous, 0.1% L-asparagine, 0.3% KH2PO4, 0.025% 
MgSO4 •7H2O, and 0.01% L-DOPA, pH 5.56) for 16 hours at 37°C and 
then 24 hours at 25°C, with shaking at 250 rpm to induce melanin pro-
duction. After incubation, the supernatants were harvested at 4,000 g for 
5 minutes, and the amount of pigment produced was determined spec-
trophotometrically at a 475-nm wavelength and converted into laccase 
units (U) by a factor of 0.001 OD = 1 U (41). Assays were repeated three to 
four times. To adjust for interexperimental variation, laccase activity of 
the clinical isolates was expressed as a ratio to H99 (positive control), and 
results were reported as the median of the repeats.
Cell wall melanin quantification
Acid-insoluble melanin production was quantified following the proto-
col of Wang and colleagues (21). Ten strains (5 with low laccase activity: 
IFN16, RCT7, RCT33, CM50, and CM36, and 5 with high laccase activity: 
CCTP2, CCTP3, CCTP10, CCTP13, and CCTP30) were subcultured on 
YPD agar and then cultured in 3 ml of YPD broth with rotation (20 rpm) 
at 25°C for 24 hours. 1.0 × 108 yeast cells were then transferred into 100 
ml of defined minimal media (41) and incubated in the dark on a shaking 
incubator at 200 rpm at 30°C, for 10 days.
Yeast cells were then pelleted, washed once with 1.0 M sorbitol in 
0.1 M sodium citrate (pH 5.0), and resuspended in 5 ml of this solution. 
The number of cells present in this resuspension was counted by hemocy-
tometry before lysis in a Precellys cell homogenizer (two 45-second peri-
ods of lysis, separated by 1 minute on ice). The cell debris was collected by 
centrifugation and resuspended in 4.0 M guanidinium isothiocyanate, a 
protein denaturant, for 30 minutes at room temperature. Cell debris was 
pelleted by centrifugation and resuspended in 6.0 M HCl at 100°C for 30 
minutes. This treatment dissolved cells completely, leaving a black/brown 
pellet of insoluble melanin. This pellet was washed in water and left to dry 
completely before being weighed and the mass per yeast cell calculated.
Capsule induction
To induce capsule production in vitro, C. neoformans isolates were inocu-
lated into SDB and grown overnight at 37°C with shaking. The following 
day, 20 μl of culture was inoculated into 5-ml capsule-inducing medium 
(DMEM with 1% NCTC-109 medium and 10% heat-inactivated FBS; 
Sigma-Aldrich) and incubated for 48 hours at 37°C with 10% CO2. Cells 
were subsequently harvested by centrifugation at 941 g for 5 minutes and 
observed by counterstaining with India ink, using a ×40 bright-field objec-
tive. Cells were measured using ImageJ software, version 1.440 (NIH), and 
the capsule diameter was calculated as the average of: (total cell diameter 
– cell body diameter) / 2 for 50 to 100 cells.
CSF survival
Human CSF was obtained from patients undergoing therapeutic lumbar 
punctures for benign intracranial hypertension at the Neurosciences day 
unit of St. George’s Hospital NHS Trust in London. CSF parameters in 
these patients, including white cell count and protein and glucose levels, 
were within the normal range for human CSF and did not contain anti-
fungal drugs.
CSF pH was determined before filter sterilization with a 0.2-μm filter 
and preserved at –80°C until use. Isolates were initially grown to the sta-
tionary phase in SDB at 37°C, with shaking at 150 rpm. Cultures were 
diluted in PBS and then inoculated into CSF at a concentration of 1 to 
2 × 106 cells/ml. Cultures were then incubated at 37°C for 96 hours with 
shaking at 150 rpm. Aliquots were collected at time point 0 and subse-
quently at 12, 24, 36, 72, and 96 hours after inoculation and plated on SDA 
for CFU counts (42). In parallel, 1% saline at a different pH, PBS, and SDB 
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were inoculated and monitored as pH, nutrient-deplete and nutrient-rich 
growth media controls, respectively. The survival slope was calculated as 
the mean rate of increase or decrease in CSF cryptococcal counts per day of 
incubation, derived by averaging the slope of the linear regression of log10 
CFU/ml over time for each isolate.
Growth curves
Isolates were grown in SDB for 48 hours to reach the stationary phase. Cul-
tures were then reinoculated into fresh SDB in 24-well flat-bottomed, trans-
parent polystyrol plates (Corning) to achieve an initial OD of 0.2 at a 600-nm 
wavelength. The plate was then incubated at 37°C with a combination of 
orbital and linear shaking (3-mm amplitude) for 48 hours (Tecan i-control 
1.7.1.12, Infinite 200 PRO Machine). OD was measured every 30 minutes, 
and the growth curves were plotted in Microsoft Excel, version 2010, after 
subtraction of the blank. Doubling time was then determined using the for-
mula: doubling time = cell concentration at time 0*egrowth rate*time (Roth V. 
2006, http://www.doubling-time.com/compute.php).
Statistics
Analyses were performed using Prism, version 6.0b (GraphPad Software) 
and Stata, version 11 (StataCorp). Associations were tested between the 
isolate virulence factors and patient clinical variables and outcome using 
linear regression for continuous variables and logistic regression for cat-
egorical variables. P values less than or equal to 0.05 were considered sig-
nificant. Fungal burden and CSF cytokines were log10 transformed before 
analysis. Spearman’s rank correlation was used to determine the correla-
tion between in vitro phenotypes and in vivo (patient) characteristics. Lin-
ear regression was used to determine the relationship between cryptococcal 
uptake by the murine macrophage-like cell line J774 and human primary 
monocyte–derived macrophages. Differences between groups were deter-
mined using the Mann-Whitney U test for non-normally distributed data 
and an unpaired t test (2-tailed) for normally distributed (log-transformed) 
data. To elucidate the relationship between different and potentially con-
founding variables, factors found to be significantly associated (P ≤ 0.05) 
with CSF fungal burden on univariable analysis were entered into a multi-
variable regression model, with fungal burden as the dependent variable. 
Cox regression was used to assess the risk of death for patients infected 
with high-uptake cryptococcal strains.
Study approval
Clinical cryptococcal isolates. Isolates used in this study were obtained from 
patients enrolled in five published clinical trials in Thailand and South 
Africa (4, 22–25). All trials received approval from the ethics committee of 
Wandsworth, London, as well as from the local research ethics committees 
in the host countries. Patients gave written informed consent, including 
for the storage and use of their clinical isolates for future research.
Human CSF. We consulted the UK National Research Ethics Service as 
well as the Research and Development Office at St. George’s University 
of London regarding the requirement for ethical review. Given that the 
lumbar punctures were being performed for a clinical indication, that the 
CSF used would otherwise have been discarded, that no clinical data were 
being collected, and that CSF samples were anonymized, rendered acel-
lular by filtration, and pooled for experimental use, ethical approval was 
deemed to be unnecessary.
Acknowledgments
We gratefully acknowledge the support of the May and Bicanic 
groups in making this study possible.
Received for publication August 29, 2013, and accepted in revised 
form February 6, 2014.
Address correspondence to: Robin C. May, Institute of Micro-
biology and Infection, School of Biosciences, University of Bir-
mingham, Birmingham, B15 2TT, United Kingdom. Phone: 
44.0.121.4145418; Fax: 44.0.1214145925; E-mail: r.c.may@bham.
ac.uk. Or to: Tihana Bicanic, Institute of Infection and Immunity, 
St. George’s University of London, London, SW17 0RE, United 
Kingdom. Phone: 44.0.2087252911; Fax: 44.0.2087253487; E-mail: 
tbicanic@sgul.ac.uk.
 1. Park BJ, Wannemuehler KA, Marston BJ, Goven-
der N, Pappas PG, Chiller TM. Estimation of the 
current global burden of cryptococcal meningi-
tis among persons living with HIV/AIDS. AIDS. 
2009;23(4):525–530.
 2. Jarvis JN, et al. High ongoing burden of cryptococ-
cal disease in Africa despite antiretroviral roll out. 
AIDS. 2009;23(9):1182–1183.
 3. Loyse A, et al. Cryptococcal meningitis: improving 
access to essential antifungal medicines in resource-
poor countries. Lancet Infect Dis. 2013;13(7):629–637.
 4. Brouwer AE, et al. Combination antifungal thera-
pies for HIV-associated cryptococcal meningitis: a 
randomised trial. Lancet. 2004;363(9423):1764–1767.
 5. Day JN, et al. Combination antifungal therapy 
for cryptococcal meningitis. N Engl J Med. 2013; 
368(14):1291–1302.
 6. Saag MS, et al. Comparison of amphotericin B with 
fluconazole in the treatment of acute AIDS-associ-
ated cryptococcal meningitis. The NIAID Mycoses 
Study Group and the AIDS Clinical Trials Group. 
N Engl J Med. 1992;326(2):83–89.
 7. Jarvis JN, Harrison TS. HIV-associated cryptococcal 
meningitis. AIDS. 2007;21(16):2119–2129.
 8. Bicanic T, et al. Independent association between 
rate of clearance of infection and clinical outcome 
of HIV-associated cryptococcal meningitis: analy-
sis of a combined cohort of 262 patients. Clin Infect 
Dis. 2009;49(5):702–709.
 9. Jarvis JN, Harrison TS. Pulmonary cryptococcosis. 
Semin Respir Crit Care Med. 2008;29(2):141–150.
 10. Sabiiti W, May RC. Mechanisms of infection by 
the human fungal pathogen Cryptococcus neofor-
mans. Future Microbiol. 2012;7(11):1297–1313.
 11. Jarvis JN, et al. The phenotype of the Crypto-
coccus-specific CD4+ memory T-cell response is 
associated with disease severity and outcome in 
HIV-associated cryptococcal meningitis. J Infect Dis. 
2013;207(12):1817–1828.
 12. Siddiqui AA, et al. IFN-γ at the site of infection deter-
mines rate of clearance of infection in cryptococcal 
meningitis. J Immunol. 2005;174(3):1746–1750.
 13. Wiesner DL, et al. Cryptococcal genotype influences 
immunologic response and human clinical outcome 
after meningitis. MBio. 2012;3(5):e00196-12.
 14. Alanio A, Desnos-Ollivier M, Dromer F. Dynamics 
of Cryptococcus neoformans-macrophage inter-
actions reveal that fungal background influences 
outcome during cryptococcal meningoencephalitis 
in humans. MBio. 2011;2(4):e00158-11.
 15. Ma H, May RC. Virulence in Cryptococcus species. 
Adv Appl Microbiol. 2009;67:131–190.
 16. Ma H, et al. The fatal fungal outbreak on Vancou-
ver Island is characterized by enhanced intracellular 
parasitism driven by mitochondrial regulation. Proc 
Natl Acad Sci U S A. 2009;106(31):12980–12985.
 17. García-Rodas R, Zaragoza O. Catch me if you can: 
phagocytosis and killing avoidance by Crypto-
coccus neoformans. FEMS Immunol Med Microbiol. 
2012;64(2):147–161.
 18. Robertson EJ, et al. Cryptococcus neoformans ex vivo 
capsule size is associated with intracranial pressure 
and host immune response in HIV-associated cryp-
tococcal meningitis. J Infect Dis. 2014;209(1):74–82.
 19. Zhu X, Williamson PR.Role of laccase in the biol-
ogy and virulence of Cryptococcus neoformans. 
FEMS Yeast Res. 2004;5(1):1–10.
 20. Erb-Downward JR, Noggle RM, Williamson PR, 
Huffnagle GB. The role of laccase in prostaglan-
din production by Cryptococcus neoformans. Mol 
Microbiol. 2008;68(6):1428–1437.
 21. Wang Y, Aisen P, Casadevall A. Melanin, melanin 
“ghosts,” and melanin composition in Cryptococcus 
neoformans. Infect Immun. 1996;64(7):2420–2424.
 22. Bicanic T, et al. Fungal burden, early fungicidal 
activity, and outcome in cryptococcal meningitis 
in antiretroviral-naive or antiretroviral-experi-
enced patients treated with amphotericin B or flu-
conazole. Clin Infect Dis. 2007;45(1):76–80.
 23. Bicanic T, et al. High-dose amphotericin B with 
flucytosine for the treatment of cryptococcal men-
ingitis in HIV-infected patients: a randomized trial. 
Clin Infect Dis. 2008;47(1):123–130.
 24. Loyse A, et al. Comparison of the early fungicidal 
activity of high-dose fluconazole, voriconazole, 
and flucytosine as second-line drugs given in com-
bination with amphotericin B for the treatment of 
HIV-associated cryptococcal meningitis. Clin Infect 
Dis. 2012;54(1):121–128.
 25. Jarvis JN, et al. Adjunctive interferon-γ immuno-
therapy for the treatment of HIV-associated cryp-
tococcal meningitis: a randomized controlled trial. 
AIDS. 2012;26(9):1105–1113.
Downloaded on May 15, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/72950
clinical medicine
2008 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 5   May 2014
 26. Rohatgi S, et al. Fcγ receptor 3A polymorphism and 
risk for HIV-associated cryptococcal disease. MBio. 
2013;4(5):e00573-13.
 27. Ma H, Croudace JE, Lammas DA, May RC. Expul-
sion of live pathogenic yeast by macrophages. Curr 
Biol. 2006;16(21):2156–2160.    
  28. Alvarez M, Casadevall A. Phagosome extrusion 
and host-cell survival after Cryptococcus neofor-
mans phagocytosis by macrophages. Curr Biol. 
2006;16(21):2161–2165.   
 29. Ma H, Croudace JE, Lammas DA, May RC. Direct 
cell-to-cell spread of a pathogenic yeast. BMC Immu-
nol. 2007;8:15.
 30. Nicola AM, Robertson EJ, Albuquerque P, Deren-
gowski Lda S, Casadevall A. Nonlytic exocytosis 
of Cryptococcus neoformans from macrophages 
occurs in vivo and is influenced by phagosomal pH. 
MBio. 2011;2(4):e00167-11.
 31. Chrétien F, Lortholary O, Kansau I, Neuville S, 
Gray F, Dromer F. Pathogenesis of cerebral Cryp-
tococcus neoformans infection after fungemia. 
J Infect Dis. 2002;186(4):522–530.
 32. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien 
F, Dromer F. Evidence of a role for monocytes in 
dissemination and brain invasion by Cryptococcus 
neoformans. Infect Immun. 2009;77(1):120–127.
 33. Ikeda R, Sugita T, Jacobson ES, Shinoda T. Effects 
of melanin upon susceptibility of Cryptococcus to 
antifungals. Microbiol Immunol. 2003;47(4):271–277.
 34. van Duin D, Casadevall A, Nosanchuk JD. Melani-
zation of Cryptococcus neoformans and Histo-
plasma capsulatum reduces their susceptibilities to 
amphotericin B and caspofungin. Antimicrob Agents 
Chemother. 2002;46(11):3394–3400.
 35. Wang Y, Casadevall A. Growth of Cryptococcus 
neoformans in presence of L-dopa decreases its 
susceptibility to amphotericin B. Antimicrob Agents 
Chemother. 1994;38(11):2648–2650.
 36. Kwon-Chung KJ, Tom WK, Costa JL. Utilization of 
indole compounds by Cryptococcus neoformans 
to produce a melanin-like pigment. J Clin Microbiol. 
1983;18(6):1419–1421.
 37. Lee SC, Dickson DW, Casadevall A. Pathology of 
cryptococcal meningoencephalitis: analysis of 
27 patients with pathogenetic implications. Hum 
Pathol. 1996;27(8):839–847.
 38. Nosanchuk JD, Rosas AL, Lee SC, Casadevall A. Mel-
anisation of Cryptococcus neoformans in human 
brain tissue. Lancet. 2000;355(9220):2049–2050.
 39. Mesa-Arango AC, Scorzoni L, Zaragoza O. It only 
takes one to do many jobs: Amphotericin B as anti-
fungal and immunomodulatory drug. Front Micro-
biol. 2012;3:286.
 40. Meyer W, et al. Consensus multi-locus sequence 
typing scheme for Cryptococcus neoformans and 
Cryptococcus gattii. Med Mycol. 2009;47(6):561–570.
 41. Hicks JK, Bahn YS, Heitman J. Pde1 phosphodi-
esterase modulates cyclic AMP levels through a 
protein kinase A-mediated negative feedback loop 
in Cryptococcus neoformans. Eukaryot Cell. 2005; 
4(12):1971–1981.
 42. Lee A, et al. Survival defects of Cryptococcus neo-
formans mutants exposed to human cerebrospinal 
fluid result in attenuated virulence in an experi-
mental model of meningitis. Infect Immun. 2010; 
78(10):4213–4225.
Downloaded on May 15, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/72950
